CMS eCQM Readiness & Reporting

About Glytec

Glytec is a commercial-stage digital health leader focused on transforming inpatient and system-wide diabetes management. Its core FDA-cleared technology, Glucommander, provides algorithm-based insulin dosing guidance, which is now integrated into the broader GlytecOne platform offering care enablement, decision support, performance analytics, and population health intelligence. The company serves over 400 hospital clients, leverages over 50 billion data points, and is strategically positioned to help health systems comply with new CMS eCQM reporting mandates for glycemic events starting in 2026. Glytec demonstrates strong value with reported ROI of 6-8x, significant cost savings per severe hypoglycemic event, and substantial improvements in clinical outcomes like reduced hypoglycemia and readmissions.

Therapeutic Areas